Article Text

other Versions

PDF
A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study
  1. Michael J Potter (michael.potter88{at}gmail.com),
  2. Cheryl C Claudio (cheryl.research{at}gmail.com),
  3. Shelagh M Szabo (shelagh.szabo{at}oxfordoutcomes.com)
  1. University of British Columbia, Canada
  2. University of British Columbia, Canada
  3. University of British Columbia, Canada

    Abstract

    Aim: To determine if reduced light dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over six months compared to bevacizumab monotherapy in neovascular age-related macular degeneration (AMD).

    Methods: Thirty-six patients with neovascular AMD were recruited for this randomised, double-masked, controlled clinical trial. Patients received intravitreal bevacizumab plus PDT using a light dose of either 25 J/cm2 (group 1) or 12 J/cm2 (group 2), or intravitreal bevacizumab plus sham PDT (group 3). Patients returned monthly for possible retreatment with bevacizumab or combination therapy (with a three-month minimum interval between combination treatments); retreatment decisions were primarily based on optical coherence tomography. The main outcome measure was the mean number of bevacizumab treatments required over six months.

    Results: Patients required a mean of 2.8 bevacizumab treatments in group 1 and 2.5 in group 2, compared to 5.1 in group 3 (p=0.005 and p<0.001, respectively).

    Conclusions: Combination bevacizumab and 25-J/cm2 or 12-J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study was powered to examine number of treatments, but not visual acuities. Nevertheless, visual acuities responded favourably in all three groups. Further studies will be helpful to explore visual outcomes.

    This clinical trial was registered on ClinicalTrials.gov, Identifier NCT00359164.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles